GSTM1 and anemia (phenotype): Excessively high Hb levels at baseline prior to treatment with rHuEPO were related with a significant increased occurrence of thromboembolism in some trials in cancer patients with anemia undergoing chemotherapy (Aapro et al., 2009; Spivak et al., 2009).